Skip to main content

Table 1 Demographical, clinical, and immunological characteristics of the study cohorts

From: Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis

  PsA (n = 34) p Abneg RA (n = 55) p 1 p 2 p 3
Naive (n = 12) MTX-IR (n = 22) Naive (n = 27) MTX-IR (n = 28)
Age, years (mean ± SD) 54.75 ± 17.18 60.18 ± 9.81 0.47 52.41 ± 17.70 58.36 ± 16.58 0.16 0.68 0.77
Female, n (%) 4 (33.3) 14 (63.6) 0.10 23 (85.2) 23 (82.1) 0.76 0.001 0.14
Disease duration, years (mean ± SD) 0.80 ± 0.24 5.83 ± 3.68 < 0.001 0.84 ± 0.95 5.68 ± 5.28 0.002 0.44 0.49
DAS44 (mean ± SD) 3.00 ± 0.42 3.34 ± 0.91 0.34 3.37 ± 1.05 3.22 ± 0.79 0.71 0.52 0.81
DAPSA (mean ± SD) 22.55 ± 8.38 28.04 ± 10.14 0.10
SJC (mean ± SD) 4.00 ± 2.67 6.43 ± 5.69 0.35 8.22 ± 7.95 7.15 ± 5.53 0.93 0.18 0.54
TJC (mean ± SD) 5.00 ± 3.16 7.00 ± 6.13 0.66 8.22 ± 7.86 8.44 ± 5.46 0.33 0.51 0.24
ESR, mm/1st hour (mean ± SD) 29.60 ± 36.94 29.10 ± 19.59 0.44 44.00 ± 25.40 37.04 ± 27.25 0.19 0.03 0.44
CRP, mg/l (mean ± SD) 16.70 ± 29.16 18.11 ± 23.41 0.70 16.99 ± 19.43 16.77 ± 24.23 0.77 0.72 1.00
Ab positivity, n (%) 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 1.00 1.00
  1. Data presented in italics have p < 0.05
  2. PsA psoriatic arthritis, RA rheumatoid arthritis, Ab autoantibody, DAS Disease Activity Score, DAPSA Disease Activity in PSoriatic Arthritis, SJC swollen joint count, TJC tender joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SD standard deviation, MTX-IR methotrexate inadequately responder, p naive PsA vs MTX-IR PsA, p1 naive Abneg RA vs MTX-IR Abneg RA, p2 naive PsA vs naive Abneg RA, p3 MTX-IR PsA vs MTX-IR Abneg RA